GJA1 and non-small cell lung carcinoma: Non-small-cell lung cancer (NSCLC) cells are more sensitive to cisplatin due to the overexpression of miR-613, and this enhanced chemosensitivity can be partially reversed by the upregulation of Gja1 [76].